The long-term effects of topical latanoprost 0.005% treatment on pupillary functions: A 2-year longitudinal study
CONCLUSION: The long-term topical latanoprost 0.005% treatment in early-stage POAG has a slight mydriatic effect on the pupil. Further longitudinal clinical studies with larger patient cohorts are necessary to better understand the effects of latanoprost on pupillary functions.PMID:38238940 | DOI:10.1177/11206721241227780 (Source: European Journal of Ophthalmology)
Source: European Journal of Ophthalmology - January 19, 2024 Category: Opthalmology Authors: Serdar Bayraktar G özde Hondur Mehmet Ali Şekeroğlu Beyhan Cengiz Özyurt Emine Şen Source Type: research
Timolol maleate, a β blocker eye drop, improved edema in a retinal vein occlusion model
CONCLUSIONS: These results indicate that timolol eye drops may be a potential option for RVO treatment.PMID:38222457 | PMC:PMC10784217 (Source: Molecular Vision)
Source: Molecular Vision - January 15, 2024 Category: Molecular Biology Authors: Shinichiro Fuma Yae Hidaka Anri Nishinaka Hiroto Yasuda Kota Aoshima Shinsuke Nakamura Hideaki Hara Masamitsu Shimazawa Source Type: research
Human experience and efficacy of omidenepag isopropyl (Eybelis ®; Omlonti®): Discovery to approval of the novel non-prostaglandin EP2-receptor-selective agonist ocular hypotensive drug
Curr Opin Pharmacol. 2024 Jan 1;74:102426. doi: 10.1016/j.coph.2023.102426. Online ahead of print.ABSTRACTMore than 75 million people worldwide suffer from ocular hypertension (OHT)-associated retinal and optic nerve degenerative diseases that cause visual impairment and can lead to blindness. In an effort to find novel pharmaceutical therapeutics to combat OHT with reduced side-effect potential, several emerging drug candidates have advanced to human proof-of-concept in recent years. One such compound is a nonprostaglandin (non-PG) EP2-receptor-selective agonist (omidenepag isopropyl ester). Omidenepag (OMD; free acid for...
Source: Current Opinion in Pharmacology - January 3, 2024 Category: Drugs & Pharmacology Authors: Najam A Sharif Source Type: research
Human experience and efficacy of omidenepag isopropyl (Eybelis ®; Omlonti®): Discovery to approval of the novel non-prostaglandin EP2-receptor-selective agonist ocular hypotensive drug
Curr Opin Pharmacol. 2024 Jan 1;74:102426. doi: 10.1016/j.coph.2023.102426. Online ahead of print.ABSTRACTMore than 75 million people worldwide suffer from ocular hypertension (OHT)-associated retinal and optic nerve degenerative diseases that cause visual impairment and can lead to blindness. In an effort to find novel pharmaceutical therapeutics to combat OHT with reduced side-effect potential, several emerging drug candidates have advanced to human proof-of-concept in recent years. One such compound is a nonprostaglandin (non-PG) EP2-receptor-selective agonist (omidenepag isopropyl ester). Omidenepag (OMD; free acid for...
Source: Current Opinion in Pharmacology - January 3, 2024 Category: Drugs & Pharmacology Authors: Najam A Sharif Source Type: research
Human experience and efficacy of omidenepag isopropyl (Eybelis ®; Omlonti®): Discovery to approval of the novel non-prostaglandin EP2-receptor-selective agonist ocular hypotensive drug
Curr Opin Pharmacol. 2024 Jan 1;74:102426. doi: 10.1016/j.coph.2023.102426. Online ahead of print.ABSTRACTMore than 75 million people worldwide suffer from ocular hypertension (OHT)-associated retinal and optic nerve degenerative diseases that cause visual impairment and can lead to blindness. In an effort to find novel pharmaceutical therapeutics to combat OHT with reduced side-effect potential, several emerging drug candidates have advanced to human proof-of-concept in recent years. One such compound is a nonprostaglandin (non-PG) EP2-receptor-selective agonist (omidenepag isopropyl ester). Omidenepag (OMD; free acid for...
Source: Current Opinion in Pharmacology - January 3, 2024 Category: Drugs & Pharmacology Authors: Najam A Sharif Source Type: research
Currently available prostanoids for the treatment of glaucoma and ocular hypertension: A review
This article offers a comprehensive review of available prostanoid analogs and explores new developments.PMID:38160646 | DOI:10.1016/j.coph.2023.102424 (Source: Current Opinion in Pharmacology)
Source: Current Opinion in Pharmacology - December 31, 2023 Category: Drugs & Pharmacology Authors: Betsy Benitez Abdelrahman M Anter Jennifer Arcuri Sanjoy K Bhattacharya Source Type: research
Currently available prostanoids for the treatment of glaucoma and ocular hypertension: A review
This article offers a comprehensive review of available prostanoid analogs and explores new developments.PMID:38160646 | DOI:10.1016/j.coph.2023.102424 (Source: Current Opinion in Pharmacology)
Source: Current Opinion in Pharmacology - December 31, 2023 Category: Drugs & Pharmacology Authors: Betsy Benitez Abdelrahman M Anter Jennifer Arcuri Sanjoy K Bhattacharya Source Type: research
A Rare Case of Latanoprost-Induced Eyelash Poliosis
Dermatitis. 2023 Nov 22. doi: 10.1089/derm.2023.0321. Online ahead of print.NO ABSTRACTPMID:38011618 | DOI:10.1089/derm.2023.0321 (Source: Dermatitis)
Source: Dermatitis - November 27, 2023 Category: Dermatology Authors: Amal Chamli Khouloud Ferchichi Refka Frioui Houda Hammami Samy Fenniche Anissa Zaouak Source Type: research
